Indaptus Therapeutics, Inc. Common Stock
Here’s whether Indaptus Therapeutics, Inc. Common Stock (INDP) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.47% over 10 days); 3-month momentum positive (+95.7%); rising volume confirms the move (2.90x 30d avg). Concerns: weak 1-year return of -62.3%. Currently 81.6% off its 52-week high. Score: +5/7.
INDP is in a confirmed uptrend, trading above both its 50-day ($2.20) and 200-day ($2.69) moving averages. An RSI of 68.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -62.3% compares to +24.4% for SPY (trailed the market by 86.7%). The current 81.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.